News | October 23, 2024
Sumitomo Corporation entered into contract with Revorf
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Subscribe To Our Newsletter & Stay Updated
